of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).ENTREMED, INC.SUMMARY OF OPERATING RESULTSThree Months EndedSeptember 30,2010
2009Total revenues
$
-
$ 3,668,333Research and development
1,291,721
2,326,969General and administrative
691,623
911,816Net (Loss) Income
(2,095,311)
84,914Net Loss per share (basic and diluted)
$
(.24)
$
(.02)attributable to common shareholdersWeighted average number of shares outstanding9,714,788
7,979,839(basic and diluted)Nine Months EndedSeptember 302010
2009Total revenues
$
-
$ 3,668,333Research and development
3,146,802
5,939,903General and administrative
2,513,527
3,082,270Acquired in-process research and development
3,000,000
-Net Loss
(9,166,041)
(6,483,034)Net Loss per share (basic)
$
(1.09)
$
(0.91)attributable to common shareholdersWeighted average number of shares outstanding (basic)
9,098,380
7,977,197Cash and short-term investments
$ 8,432,703
$10,027,567CONTACT:Ginny Dunn EntreMed, Inc. Associate DirectorCorporate Communications & Investor Relations240-864-2643
'/>"/>
SOURCE EntreMed, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related medicine technology :1.
EntreMed Receives Notice of NASDAQ Compliance2.
EntreMed Secures $5.1 Million in Registered Direct Offering and Enters into Agreement for Rights to License ENMD-2076 in China3.
EntreMed Receives NASDAQ Listing Rule 5550(b)(2) Determination Letter4.
EntreMed Reports Second Quarter 2010 Financial Results5.
EntreMeds ENMD-2076 Active in Solid and Hematological Cancers6.
Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients7.
EntreMed Presents Initial Clinical Results for ENMD-20768.
EntreMed Receives New Patent for 2-Methoxyestradiol Analogs9.
EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting10.
EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting11.
EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting